Retatrutide

Sinónimos: Retatrutide, LY3437943, Triple agonist peptide, GIP/GLP-1/glucagon receptor agonist

Retatrutide is a synthetic peptide engineered to interact with three distinct incretin and metabolic receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. This triple agonist profile places it in a class of its own among current metabolic research compounds, where most clinical candidates target only one or two of these pathways. The molecule was designed to amplify the metabolic benefits of GLP-1 and GIP receptor activation while adding the energy-expenditure and lipid-mobilizing effects that glucagon receptor engagement can provide.

Structurally, retatrutide is a 39-amino-acid peptide with a C20 fatty diacid moiety attached via a linker to the peptide backbone. This lipidation strategy is a well-established approach in the field to extend circulation time by promoting binding to serum albumin, which slows renal clearance and supports once-weekly dosing in clinical settings. The peptide sequence incorporates several non-proteinogenic amino acids and aib substitutions that contribute to its stability against enzymatic degradation, particularly by DPP-4. The molecular formula, C221H342N46O68, reflects the complexity of the construct, and its molecular weight of approximately 4731 Da is typical for a lipidated peptide of this size.

In research contexts, retatrutide has drawn significant attention for its dose-dependent effects on body weight and glycemic parameters. Preclinical and early-phase clinical data suggest that simultaneous activation of GIP, GLP-1, and glucagon receptors may produce greater reductions in body weight than selective GLP-1 receptor agonists alone, though the exact contribution of each receptor arm continues to be investigated. For procurement professionals and formulation scientists, retatrutide is available as a high-purity lyophilized powder, typically ≥98% by HPLC, and is supplied with full analytical documentation to support method development, receptor binding studies, and metabolic assay validation.

Función

• Triple receptor agonism: Simultaneously activates GIP, GLP-1, and glucagon receptors, a profile unique among advanced metabolic peptides.
• Metabolic rate modulation: Glucagon receptor engagement is associated with increased energy expenditure and lipid oxidation in preclinical models.
• Appetite regulation: GLP-1 and GIP receptor activation contribute to reduced food intake and altered satiety signaling.
• Glycemic control: Enhances glucose-dependent insulin secretion and improves insulin sensitivity in animal studies.
• Body weight management: Investigational data indicate dose-dependent reductions in body weight and adiposity.

Source & Standardization

• Source: Synthetic solid-phase peptide synthesis (SPPS)
• Purification: Reverse-phase high-performance liquid chromatography (RP-HPLC)
• Standardization: ≥98.0% purity by HPLC; identity confirmed by mass spectrometry
• Forms: Lyophilized white to off-white powder
• Aplicaciones: Metabolic research, receptor pharmacology, obesity and diabetes studies, analytical method development

Especificaciones

Documentation & Supply

• Monthly capacity: 50–100 grams (scale-up available upon request)
• Plazo de entrega: 3-5 días laborables (artículos en stock)
• Documentación: COA, MSDS, TDS, and additional analytical data (HPLC, MS) provided with every shipment
• Embalaje: Sealed glass vials under inert gas; secondary packaging to ensure stability during transit

Solicitud de presupuesto

• LyvBio S.L. — Correo electrónico: info@lyvbio.com